Author: Nichols Martin|| Date Published: June 10, 2021
Army Contracting Command has awarded Merck (NYSE: MRK) a one-year, $1.2 billion contract to deliver nearly 1.7 million courses of molnupiravir, an investigational oral antiviral agent intended to support the treatment of COVID-19 patients.
The Department of Defense said Wednesday the full contract amount was obligated on the firm-fixed-price contract using Coronavirus Aid, Relief and Economic Security Act funds.
Molnupiravir, also known as MK-4482, is undergoing a late-stage clinical trial, dubbed MOVe-OUT. Merck secured the contract through an online solicitation and will deliver the antiviral drug to the U.S. government once the Food and Drug Administration grants emergency use authorization.
Ridgeback Biotherapeutics works with Merck in the COVID-19 treatment development effort and the latter company expects more than 10 million courses of antiviral therapy to be available at the end of the year.
Northrop Grumman has secured a $303.6 million indefinite-delivery/indefinite-quantity contract for the repair and return of radar components used on F-16…
Quantum computing firm IonQ has unveiled plans to acquire Skyloom Global, a Colorado-based developer of optical communication systems for space-based quantum networks. The…
Shareholders at identity security company CyberArk have approved Palo Alto Networks’ proposed acquisition offer. Cyberthreats are escalating, and government data…
